| Registered No. |
Intervention |
Patient |
Phase |
Start Year |
Sponsor |
Status |
| NCT01008358 |
CP 675,206 (tremelimumab) - Anti-CTLA antibody |
Unresectable HCC |
II |
2008 |
Clinica Universidad de Navarra, Universidad de Navarra |
Completed |
| NCT00966251 |
Pidilizumab – anti-PD1 antibody |
Not operational HCC |
I/II |
2009 |
CureTech Ltd. |
Terminated due to slow accrual |
| NCT01658878 |
Nivolumab – anti-PD1 antibody |
Advanced HCC |
I |
2012 |
Bristol-Myers Squibb |
Recruiting |
| NCT01853618 |
Tremelimumab – anti-CTLA4 antibody |
Advanced HCC |
I |
2013 |
National Cancer Institute (NCI) |
Recruiting |
| NCT02519348 |
MEDI4736 (anti-PD-L1 antibody), tremelimumab (anti-CTLA4 antibody) |
unresectable HCC |
I/II |
2015 |
MedImmune LLC |
Not yet recruiting |
